Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
APLT
Applied Therapeutics, Inc.
The company is developing CNS and neurologic disease therapies (govorestat and related ARI programs), aligning with neuropsychiatric drug development.
|
$38.05M |
$0.27
+6.38%
|
|
PDSB
PDS Biotechnology Corporation
Company is a oncology-focused biotech developing novel immunotherapies for HPV-related cancers (HPV16+ HNSCC).
|
$37.93M |
$0.81
+8.10%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$36.48M |
$13.89
-0.43%
|
|
JANL
Janel Corporation
Life Sciences subsidiaries provide contract manufacturing services (antibody/reagent production, viral vector production).
|
$36.18M |
$32.00
|
|
RNTX
Rein Therapeutics Inc.
IPF/related fibrotic orphan indications classify Rein's lead assets as addressing a rare disease space.
|
$35.89M |
$1.55
+6.51%
|
|
FGEN
FibroGen, Inc.
FibroGen's FG-3246 is an oncology-focused therapeutic program, making Biotech - Oncology a core investment theme.
|
$35.77M |
$8.41
-1.75%
|
|
VERU
Veru Inc.
Veru's lead asset enobosarm is an oral small molecule therapeutic.
|
$35.77M |
$2.46
+3.14%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$35.70M |
$5.34
+1.71%
|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$35.48M |
$1.95
+1.56%
|
|
MURA
Mural Oncology plc
Company develops oncology-focused immunotherapies, including engineered cytokine therapies (nemvaleukin) and related assets.
|
$35.00M |
$2.02
-3.57%
|
|
NMTC
NeuroOne Medical Technologies Corporation
sEEG-based drug delivery system platform enabling localized therapeutic delivery from neural implants.
|
$34.86M |
$0.71
+3.77%
|
|
DYAI
Dyadic International, Inc.
Company directly produces recombinant proteins and enzymes (e.g., RHSA, transferrin, DNase1, RNase inhibitors, FGF, lactalbumin, lactoferrin) for life sciences, diagnostics, and food/industrial uses.
|
$33.84M |
$0.95
-0.46%
|
|
VNRX
VolitionRx Limited
Nu.Q Discover and Nu.Q Cancer positioning create companion diagnostic opportunities and biomarker-driven patient stratification.
|
$33.49M |
$0.31
+3.98%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
|
$33.06M |
$2.23
+5.92%
|
|
CCEL
Cryo-Cell International, Inc.
Cryo-Cell's core business is private cord blood and cord tissue stem cell collection, processing, and long-term cryogenic storage, aligning with the Biotech - Cell Therapy investable theme.
|
$32.71M |
$4.43
-0.36%
|
|
RDGL
Vivos Inc.
RDGL's core offering is radiopharmaceutical therapy using Y-90 for targeted cancer treatment.
|
$32.55M |
$0.07
|
|
BRNS
Barinthus Biotherapeutics plc
Company is pivoting to immunology/inflammation therapeutics and is advancing T‑cell immunotherapies (SNAP-TI), with VTP-1000 for celiac disease as lead candidate.
|
$31.52M |
$0.72
+1.27%
|
|
PLUR
Pluri Inc.
PluriCDMO provides cell-therapy manufacturing services, generating revenue and serving as a core business line.
|
$31.07M |
$3.90
+4.28%
|
|
RADX
Radiopharm Theranostics Limited
Core product category: Radiopharmaceuticals used for diagnostic imaging and therapy in oncology.
|
$30.63M |
$4.75
+1.71%
|
|
BTAI
BioXcel Therapeutics, Inc.
BXCL501 is a small-molecule drug delivered as an oral dissolving film; fits 'Oral Small Molecule Therapeutics'.
|
$30.28M |
$2.10
+9.69%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$29.91M |
$0.86
+3.31%
|
|
IGC
IGC Pharma, Inc.
Direct Alzheimer’s disease therapeutics pipeline with IGC-AD1 and disease-modifying candidates, the core product focus.
|
$29.00M |
$0.32
+1.64%
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$28.97M |
$1.08
-1.82%
|
|
PASG
Passage Bio, Inc.
PBFT02 is Passage Bio's lead gene therapy program directly developed by the company.
|
$28.58M |
$8.65
-3.65%
|
|
ELUT
Elutia Inc.
EluPro embodies a Drug Delivery Platform delivering antibiotics from the biomatrix at the implant site.
|
$28.53M |
$0.68
+9.26%
|
|
SCYX
SCYNEXIS, Inc.
SCYNEXIS's ibrexafungerp is a lead oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' category.
|
$28.43M |
$0.68
+1.26%
|
|
JSPR
Jasper Therapeutics, Inc.
Core product briquilimab is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$28.36M |
$1.75
-0.29%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
Ketamir-2 is a novel oral small-molecule therapeutic targeting neuropathic pain, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$28.03M |
$1.48
+1.72%
|
|
IKNA
Ikena Oncology, Inc.
ImageneBio's lead asset IMG-007 is a monoclonal antibody targeting OX40 for immunological/inflammatory diseases, aligning with Immunology Therapeutics.
|
$27.79M |
$7.11
|
|
APUS
Apimeds Pharmaceuticals US, Inc
APUS's lead product Apitox is a bee venom-based immunology/anti-inflammatory therapy targeting OA pain and potential MS, fitting the Immunology Therapeutics category.
|
$27.54M |
$2.30
+17.95%
|
|
TLPH
Talphera, Inc.
Talphera is developing ready-to-use pre-filled syringe formulations (e.g., Fedsyra) for nafamostat-based therapies.
|
$26.88M |
$1.31
-0.38%
|
Showing page 20 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
